CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0014 (clinicaltrials.gov NCT No: NCT00376948)
Title:Phase II Trial of Novasoy, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer (2005-006)
Principal Investigator:James L. Abbruzzese
Treatment Agent:Erlotinib; Gemcitabine; Novasoy
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
Novasoy“, gemcitabine, and erlotinib hydrochloride can help to control
advanced pancreatic cancer. The safety of this treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase II
Treatment Agents:Erlotinib
Gemcitabine
Novasoy
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Hospitalization is not required for this study.
Supported By:Karmanos Cancer Center, Wayne State University
OSI Pharmaceuticals (Supporter)
Return Visit:Days 1, 8, & 15 of each 28 day cycle.
Home Care:Patients may take erlotinib and Novasoy‚ at home as these are oral
medications.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:James L. Abbruzzese
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults